Figure 5.
Humanized therapeutic antibody eradicate HBV in synergistic combination with ETV. (A–E) AAV-HBV and HBV-transgenic mice (n = 8/group; HBsAg: 1 × 103–2 × 104 IU/mL) were administrated with 162 intravenously as indicated by blue arrows, the time of blood sampling was indicated by red arrows. Vehicle was injected intravenously as control. (A) Schematic representation of the combination therapy procedure used for (B–E). (B,D) Time kinetic of virological indicators in male AAV-HBV mice. Serum levels of (B) HBsAg, (D) HBV-DNA. (C,E) Time kinetic of virological indicators in male HBV-tg mice. Serum levels of (C) HBsAg, (E) HBV-DNA. Results were representative of three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.